一个患有转移性癌症的患者的美特罗尼达诱导脑病变
Anish K Sethi1, Elizabeth O'Connor2, Kenil Upadhyay2
1School of Medicine, Drexel University College of Medicine, West Reading, USA.
Cureus
|February 27, 2026
概括
甲尼达诱导的脑病变 (MIE) 是长期使用甲尼达的罕见副作用. 早期大脑MRI推给长期服用美特罗尼达的患者呈现神经症状,以帮助诊断和管理.
科学领域:
- 神经学 神经学
- 毒理学 毒理学 毒理学
- 在瘤学瘤学.
背景情况:
- 甲尼达诱导脑病变 (MIE) 是一种罕见但严重的不良反应,与长期的甲尼达治疗有关.
- 患有复杂疾病的患者,如转移性癌症和需要长期抗生素治疗的,处于危险之中.
- 神经症状可能是急性,并模仿其他条件,使诊断复杂化.
研究的目的:
- 在患有转移性癌症的患者中报告一例美트로尼达诱导的脑病变.
- 突出与MIE相关的诊断挑战和成像发现.
- 强调早期神经成像和多学科护理在管理MIE中的重要性.
主要方法:
- 一个病人的病例报告呈现急性脑病变特征.
- 对临床表现,神经学检查和诊断工作的审查.
- 大脑磁共振成像 (MRI) 发现表明MIE.
主要成果:
- 患者表现出困惑和虚弱,检查结果可能因先前的中风而混.
- 头部CT无法得出结论,但脑部MRI显示大脑小脑牙核中的双边,这是MIE的特征.
- 这位患者长期服用美特罗尼达治疗转移性癌症的继发性复杂.
结论:
- 怀疑的高指数和早期的大脑MRI对于在长期服用美트로尼达的患者中诊断MIE至关重要.
- 及时诊断和停止使用甲尼达是防止不可逆转的神经损伤的必要条件.
- 在患有持续缺陷的患者中,早期涉及神经病学和息护理服务可以优化生活质量.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
691
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
691
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
744
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
744
Electron Transport Chain: Complex I and II
19.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
19.2K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
979
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
979
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
42
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
42
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
316
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
316


